Are Doctors Ready for AI to Steal Their Stethoscopes?
'To be a good doctor, you need a broad education — philosophy included,' said Eduardo de Teresa Galván, MD, PhD, honorary board member of the SEC and a cardiology expert. Speaking to Univadis Spain , a Medscape Network platform, de Teresa added, 'Physicians should ask themselves more often, 'Why?''
Pilar García Velasco, director of Projects and Institutional Relations at Círculo de Bellas Artes, explained to Univadis Spain that the series was designed to 'explore how science and the humanities intersect and inform each other, so we can better understand today's challenges.' Together with the SEC, the organizers selected three core topics: the impact of artificial intelligence (AI) on healthcare, the debate on life extension, and the medicalization of existential issues such as boredom. García Velasco emphasized that the goal was not to reach definitive conclusions but rather to spark curiosity and encourage ongoing reflection among attendees.
AI Impact
The opening panel, The Doctor-Patient Relationship in the Era of Artificial Intelligence , examined the current and potential roles of AI in healthcare. The panelists discussed AI's contributions to test result interpretation and diagnostic efficiency. De Teresa underscored both the promise and the pitfalls: 'This should mean that doctors have more time to devote to cultivating the essential doctor-patient relationship, but experience tells us that every time a technological advance has emerged that lightens the burden on medical professionals, the reaction has been to overload their schedules with more patients.'
He also urged for meaningful physician involvement in technology development: 'We must advise those who develop the models so that they are as useful as possible to improve care for our patients.' De Teresa stressed the urgent need to reform medical education in response to technological shifts: 'It makes no sense for us to continue training future doctors as we are doing now. The question is how to do it; it is a debate that must be opened and will be very complex and difficult,' he added.
Panelists included de Teresa; Nikos Kastanos, MD, CEO of Medical Trends and president and co-founder of the Hippocratic Movement; with Pilar López García, PhD, dean of the Faculty of Medicine at the Autonomous University of Madrid, as moderator.
Life Span
The second discussion, Who Wants to Live Forever , addressed whether immortality — or at least a significant life extension — is possible or desirable. The session highlighted the intersection of philosophy and biology, from exploring the biological feasibility of a longer life to reflecting on philosophical meanings.
De Teresa shared a philosophical view, stating, 'What makes life interesting is that our time is limited, and we have to try to make the most of it. If we had much more time, everything would end up repeating itself over and over again.'
The panelists included Carlos López-Otín, PhD, professor of Biochemistry and Molecular Biology at the University of Oviedo; Iván de los Ríos, PhD, professor of Philosophy at the Autonomous University of Madrid; and Andrea Kallmeyer, MD, cardiologist at Fundación Jiménez Díaz University Hospital, as moderators.
Boredom Debate
The final round titled Is Boredom a Medical Problem? critically examined healthcare boundaries amid societal tendencies to medicalize ordinary experiences and challenges posed by an aging population. 'This could ultimately bankrupt our welfare state. We must reflect on this as a society,' warned de Teresa.
Panelists were Josefa Ros, PhD, professor of Social Psychology and lead researcher in Boredom Studies at the Complutense University of Madrid; José Luis Puerta, MD, PhD, coordinator of the Department of Anthropology of Medicine at the Center for Human Evolution and Behavior (Carlos III Health Institute-Complutense University of Madrid); and Valerio Rocco, PhD, director of Círculo de Bellas Artes; with Marisa Crespo, MD, PhD, vice president-elect of the SEC, as moderator.
Conclusion
Both the SEC and Círculo de Bellas Artes expressed satisfaction with the series' success in terms of attendance and content quality — all seats were sold. 'The success of this collaboration with the SEC has led us to consider new joint proposals that will help us continue to delve into the links between science and the humanities,' García Velasco said. De Teresa noted that future editions of the series may expand beyond Madrid to foster broader engagement and decentralize programming.
García Velasco and de Teresa reported having no relevant conflicts of interest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
👟 The silent mistake at Valdebebas that could lead to injuries
In the sophisticated gym of Valdebebas, where every minute of training is optimized, a silent practice has become habitual among many Real Madrid players: doing strength exercises with highly cushioned running shoes. What seems like a minor wardrobe choice may be directly affecting the quality of strength training and, in the worst-case scenario, increasing the risk of injury. 👟 The wrong footwear: more common than it seems According to the photos published by the club on its official channels, a good part of the squad does squats, lunges, deadlifts, or plyometric exercises with shoes designed for running long distances, not for weightlifting. These shoes, known for their high cushioning and soft sole, are designed to absorb impacts, but not to provide stability, as even the manufacturers themselves recognize. In a graphic way, using this type of footwear for strength training is like lifting weights on a mattress. 🤕 What's at stake? Wasted performance: the strength developed in exercises like deadlifts or squats depends on a stable base. If the shoe absorbs part of that force, the player wastes part of the benefits. Risk of functional injuries: the instability of a soft shoe can lead to micromovements in ankles, knees, or hips. In elite athletes who already carry high volumes of load, this can result in tendinitis, sprains, or chronic back overloads. Postural misalignment: many running shoes have elevated heels and curved soles. This modifies the athlete's natural posture, something especially delicate in exercises where the spine and pelvis must be kept aligned and firm. ✅ What should they be using? The ideal is to use weightlifting shoes or flat, firm shoes like CrossFit, such as those used by Carvajal, Rudiger, or Mbappé in the photos disseminated by Real Madrid. 👍🏻 Does training with unstable shoes provide benefits? Training strength with unstable shoes can have certain benefits for the professional footballer, but only if done in a specific, controlled, and targeted manner. For example, training with controlled instability improves motor control and strengthens ankles, knees, and hips, which can be beneficial in real game situations. Real Madrid has won Champions Leagues, leagues, and super cups by taking care of every minor detail. But in the high-performance environment, small margins create enormous differences. And something as seemingly trivial as gym footwear can be the difference between a brilliant season... or an injury that changes everything. This article was translated into English by Artificial Intelligence. You can read the original version in 🇪🇸 here. 📸 PIERRE-PHILIPPE MARCOU - AFP or licensors
Yahoo
36 minutes ago
- Yahoo
3 Healthcare Stocks Paying the Highest Dividends of 2025
Key Points SIGA Technologies has a sky-high dividend yield that comes with a catch. Pfizer's dividend remains strong despite a looming patent cliff. Spok Holdings offers an attractive dividend and outstanding growth. 10 stocks we like better than Pfizer › The healthcare sector has long been a favorite for income investors -- and for good reason. Many healthcare stocks offer attractive dividend yields. Some stocks stand out more than others, though. Here are the three healthcare stocks paying the highest dividends in 2025. 1. SIGA Technologies SIGA Technologies (NASDAQ: SIGA) focuses primarily on developing drugs for treating orthopoxviruses. Its flagship product is TPOXX, an antiviral medication that's approved in the U.S. and Canada for treating smallpox and in Europe, Japan, and the U.K. for treating smallpox, mpox, cowpox, and vaccinia complications. The company's dividend yield is a lofty 9.29%. However, there's something investors should know about SIGA's dividend. The drugmaker doesn't pay a regular dividend but, instead, has declared special cash dividends for four consecutive years. Special cash dividends usually aren't viewed as favorably by income investors as established programs that pay dividends on a monthly or quarterly basis. The risk that a company will decide against paying a special cash dividend in the future is probably higher than the risk that a company will suspend a regular dividend. SIGA's ability to pay dividends in the future depends largely on how seriously governments perceive the threat posed by smallpox, mpox, and other orthopoxviruses. For now, the threat level is high. That probably bodes well for the company declaring a special cash dividend in 2026, but it's difficult to predict what will happen with SIGA's dividend beyond then. 2. Pfizer Pfizer (NYSE: PFE) is the most well-known of the high-paying healthcare dividend stocks on this list. The company was founded in 1849. Today, it's one of the biggest drugmakers on the planet, with a market cap of over $130 billion and a lineup that includes multiple blockbuster drugs. Income investors have a lot to like about Pfizer. Its forward dividend yield stands at 7.32%. The company has paid a dividend for 346 consecutive quarters and has increased its dividend for 16 consecutive years. Its management team remains committed to sustaining and growing the dividend. Pfizer faces some challenges that could limit how much it's able to increase the dividend over the next few years, though. By the end of 2028, the company will lose patent protection for kidney cancer drug Inlyta, autoimmune disease drug Xeljanz, blood thinner Eliquis, breast cancer drug Ibrance, prostate cancer drug Xtandi, rare-disease franchise Vyndaqel/Vyndamx, and Mektovi, which treats melanoma and non-small cell lung cancer. While this patent cliff admittedly looks daunting, Pfizer's dividend shouldn't be in danger. The drugmaker has several rising stars, including migraine therapy Nurtec ODT and cancer drugs Padcev, Lorbrena, and Elrexfio. Pfizer's pipeline is also loaded with promising candidates, including 30 late-stage programs. 3. Spok Holdings Spok Holdings (NASDAQ: SPOK) specializes in healthcare communication and collaboration solutions. The company's flagship product, Spok Care Connect, is a unified communication platform that provides closed-loop communication, secure messaging, and collaboration capabilities to clinical teams. While Spok mainly focuses on hospitals, it also sells products to large government agencies, public-safety institutions, academic institutions, and other commercial customers. There's good news and bad news with Spok's dividend. First, the bad news: Don't expect dividend increases. Spok hasn't increased its dividend since 2022. The good news, though, is that the dividend is attractive, with a forward yield of 6.75%. Want more good news? Spok's business is booming. The company's earnings jumped 33% year over year in the second quarter of 2025. Its software operations bookings were 34% higher than the prior-year period. Unsurprisingly, Spok's stock has also performed well and is handily beating the market so far this year. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. 3 Healthcare Stocks Paying the Highest Dividends of 2025 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
👟 The silent mistake at Valdebebas that could lead to injuries
In the sophisticated gym of Valdebebas, where every minute of training is optimized, a silent practice has become habitual among many Real Madrid players: doing strength exercises with highly cushioned running shoes. What seems like a minor wardrobe choice may be directly affecting the quality of strength training and, in the worst-case scenario, increasing the risk of injury. 👟 The wrong footwear: more common than it seems According to the photos published by the club on its official channels, a good part of the squad does squats, lunges, deadlifts, or plyometric exercises with shoes designed for running long distances, not for weightlifting. These shoes, known for their high cushioning and soft sole, are designed to absorb impacts, but not to provide stability, as even the manufacturers themselves recognize. In a graphic way, using this type of footwear for strength training is like lifting weights on a mattress. 🤕 What's at stake? Wasted performance: the strength developed in exercises like deadlifts or squats depends on a stable base. If the shoe absorbs part of that force, the player wastes part of the benefits. Risk of functional injuries: the instability of a soft shoe can lead to micromovements in ankles, knees, or hips. In elite athletes who already carry high volumes of load, this can result in tendinitis, sprains, or chronic back overloads. Postural misalignment: many running shoes have elevated heels and curved soles. This modifies the athlete's natural posture, something especially delicate in exercises where the spine and pelvis must be kept aligned and firm. ✅ What should they be using? The ideal is to use weightlifting shoes or flat, firm shoes like CrossFit, such as those used by Carvajal, Rudiger, or Mbappé in the photos disseminated by Real Madrid. 👍🏻 Does training with unstable shoes provide benefits? Training strength with unstable shoes can have certain benefits for the professional footballer, but only if done in a specific, controlled, and targeted manner. For example, training with controlled instability improves motor control and strengthens ankles, knees, and hips, which can be beneficial in real game situations. Real Madrid has won Champions Leagues, leagues, and super cups by taking care of every minor detail. But in the high-performance environment, small margins create enormous differences. And something as seemingly trivial as gym footwear can be the difference between a brilliant season... or an injury that changes everything. This article was translated into English by Artificial Intelligence. You can read the original version in 🇪🇸 here. 📸 PIERRE-PHILIPPE MARCOU - AFP or licensors
